Argenx
ARGX
#456
Rank
A$74.84 B
Marketcap
A$1,209
Share price
-0.85%
Change (1 day)
13.01%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): A$13.55

According to Argenx 's latest financial reports the company's current EPS (TTM) is A$12.76. In 2024 the company made an earnings per share (EPS) of A$20.03 an increase over its 2023 EPS that were of A-$7.43.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$13.55-32.37%
2024A$20.03-369.77%
2023A-$7.43-60.46%
2022A-$18.7863.33%
2021A-$11.50-40.37%
2020A-$19.28183.47%
2019A-$6.80123.09%
2018A-$3.0554.93%
2017A-$1.9714.07%
2016A-$1.7313.05%
2015A-$1.53-36.34%
2014A-$2.40209.04%
2013A-$0.78-33.99%
2012A-$1.18185.59%
2011A-$0.41